Metabolic characteristics in patients with COVID-19 and no-COVID-19 interstitial pneumonia with mild-to-moderate symptoms and similar radiological severity.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
28 10 2021
Historique:
received: 26 04 2021
revised: 10 08 2021
accepted: 11 08 2021
pubmed: 12 10 2021
medline: 11 11 2021
entrez: 11 10 2021
Statut: ppublish

Résumé

It is known that the highest COVID-19 mortality rates are among patients who develop severe COVID-19 pneumonia. However, despite the high sensitivity of chest CT scans for diagnosing COVID-19 in a screening population, the appearance of a chest CT is thought to have low diagnostic specificity. The aim of this retrospective case-control study is based on evaluation of clinical and radiological characteristics in patients with COVID-19 (n = 41) and no-COVID-19 interstitial pneumonia (n = 48) with mild-to-moderate symptoms. To this purpose we compared radiological, clinical, biochemical, inflammatory, and metabolic characteristics, as well as clinical outcomes, between the two groups. Notably, we found similar radiological severity of pneumonia, which we quantified using a disease score based on a high-resolution computed tomography scan (COVID-19 = 18.6 ± 14.5 vs n-COVID-19 = 23.2 ± 15.2, p = 0.289), and comparable biochemical and inflammatory characteristics. However, among patients without diabetes, we observed that COVID-19 patients had significantly higher levels of HbA1c than n-COVID-19 patients (COVID-19 = 41.5 ± 2.6 vs n-COVID-19 = 38.4 ± 5.1, p = 0.012). After adjusting for age, sex, and BMI, we found that HbA1c levels were significantly associated with the risk of COVID-19 pneumonia (odds ratio = 1.234 [95%CI = 1.051-1.449], p = 0.010). In this retrospective case-control study, we found similar radiological and clinical characteristics in patients with COVID-19 and n-COVID-19 pneumonia with mild-to-moderate symptoms. However, among patients without diabetes HbA1c levels were higher in COVID-19 patients than in no-COVID-19 individuals. Future studies should assess whether reducing transient hyperglycemia in individuals without overt diabetes may lower the risk of SARS-CoV-2 infection.

Sections du résumé

BACKGROUND AND AIMS
It is known that the highest COVID-19 mortality rates are among patients who develop severe COVID-19 pneumonia. However, despite the high sensitivity of chest CT scans for diagnosing COVID-19 in a screening population, the appearance of a chest CT is thought to have low diagnostic specificity. The aim of this retrospective case-control study is based on evaluation of clinical and radiological characteristics in patients with COVID-19 (n = 41) and no-COVID-19 interstitial pneumonia (n = 48) with mild-to-moderate symptoms.
METHODS AND RESULTS
To this purpose we compared radiological, clinical, biochemical, inflammatory, and metabolic characteristics, as well as clinical outcomes, between the two groups. Notably, we found similar radiological severity of pneumonia, which we quantified using a disease score based on a high-resolution computed tomography scan (COVID-19 = 18.6 ± 14.5 vs n-COVID-19 = 23.2 ± 15.2, p = 0.289), and comparable biochemical and inflammatory characteristics. However, among patients without diabetes, we observed that COVID-19 patients had significantly higher levels of HbA1c than n-COVID-19 patients (COVID-19 = 41.5 ± 2.6 vs n-COVID-19 = 38.4 ± 5.1, p = 0.012). After adjusting for age, sex, and BMI, we found that HbA1c levels were significantly associated with the risk of COVID-19 pneumonia (odds ratio = 1.234 [95%CI = 1.051-1.449], p = 0.010).
CONCLUSIONS
In this retrospective case-control study, we found similar radiological and clinical characteristics in patients with COVID-19 and n-COVID-19 pneumonia with mild-to-moderate symptoms. However, among patients without diabetes HbA1c levels were higher in COVID-19 patients than in no-COVID-19 individuals. Future studies should assess whether reducing transient hyperglycemia in individuals without overt diabetes may lower the risk of SARS-CoV-2 infection.

Identifiants

pubmed: 34629249
pii: S0939-4753(21)00406-3
doi: 10.1016/j.numecd.2021.08.035
pmc: PMC8372447
pii:
doi:

Substances chimiques

Glycated Hemoglobin A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3227-3235

Informations de copyright

Copyright © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare that they have no personal or financial conflicts of interest.

Auteurs

Stefano Rizza (S)

Department of Systems Medicine, University of Rome Tor Vergata, Italy. Electronic address: stefano.rizza@uniroma2.it.

Alessandro Nucera (A)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Marcello Chiocchi (M)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy.

Alfonso Bellia (A)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Daniele Mereu (D)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Gianluigi Ferrazza (G)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Marta Ballanti (M)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Francesca Davato (F)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Giovanni Di Cola (G)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Claudio O Buonomo (CO)

Department of Surgical Science, University of Rome Tor Vergata, Italy.

Luca Coppeta (L)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy.

Gianluca Vanni (G)

Department of Surgical Science, University of Rome Tor Vergata, Italy.

Romualdo Gervasi (R)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Marina Cardellini (M)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Davide Lauro (D)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Massimo Federici (M)

Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH